LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

LLY

917.46

+0.11%↑

JNJ

237.66

+0.19%↑

ABBV

206.13

-1.03%↓

NVS

148.1

-1.11%↓

AZN

188.8

+0.2%↑

Kodu・Aktsiate loetelu・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Suletud

SektorTervishoid

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-0.05% downside

Uudiste sentiment

By Acuity

50%

155 / 350 Pingereas Healthcare

Mirati Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

19. märts 2026, 18:34 UTC

Tulu

Canada to Allow Smaller Companies to Ax Quarterly Earnings Reports in Pilot

19. märts 2026, 17:43 UTC

Suurimad hinnamuutused turgudel

Ecolab Dips on Report of Deal for CoolIT Systems With KKR

19. märts 2026, 23:47 UTC

Tulu

COSCO SHIPPING Holdings: Geopolitical Tensions Will Continue Driving Regional Fragmentation >1919.HK

19. märts 2026, 23:47 UTC

Tulu

COSCO SHIPPING Holdings: Container Shipping Market Saw Fluctuating, Declining Freight Rates >1919.HK

19. märts 2026, 23:47 UTC

Tulu

COSCO SHIPPING Holdings 2025 Rev CNY219.50B Vs. CNY233.86B >1919.HK

19. märts 2026, 23:47 UTC

Tulu

COSCO SHIPPING Holdings 2025 Net CNY30.86B Vs. Net CNY49.17B >1919.HK

19. märts 2026, 23:39 UTC

Tulu

Li Ning 2025 Net CNY2.94B Vs. Net CNY3.01B >2331.HK

19. märts 2026, 23:39 UTC

Tulu

Li Ning: Will Continue Targeting Consumer Needs, Strengthening User Engagement >2331.HK

19. märts 2026, 23:39 UTC

Tulu

Li Ning: Outdoor Category Continued Growing >2331.HK

19. märts 2026, 23:38 UTC

Tulu

Li Ning 2025 Rev CNY29.60B Vs. CNY28.68B >2331.HK

19. märts 2026, 23:33 UTC

Market Talk

Gold Edges Lower on Inflation Concerns, Dimmed Fed Rate-Cut Hopes -- Market Talk

19. märts 2026, 22:42 UTC

Omandamised, ülevõtmised, äriostud

Unilever in Talks to Separate Food Business and Combine It With McCormick -- WSJ

19. märts 2026, 22:42 UTC

Omandamised, ülevõtmised, äriostud

McCormick Has a Market Value of Around $14.8B -- WSJ

19. märts 2026, 22:42 UTC

Omandamised, ülevõtmised, äriostud

Unilever in Talks to Combine Food Business With McCormick, Sources Say -- WSJ

19. märts 2026, 22:42 UTC

Omandamised, ülevõtmised, äriostud

All-Stock Unilever-McCormick Deal Could Come Together Within Weeks, Sources Say -- WSJ

19. märts 2026, 22:23 UTC

Market Talk

FedEx Says It Can Raise Prices to Offset Higher Fuel Costs -- Market Talk

19. märts 2026, 22:09 UTC

Market Talk

Uudisväärsed sündmused

Australian Transport Stocks to Trade at Discount On Fuel Risks -- Market Talk

19. märts 2026, 22:06 UTC

Market Talk

Sigma Healthcare's New Bull Expects Profit Margins to Widen -- Market Talk

19. märts 2026, 22:04 UTC

Tulu

Omandamised, ülevõtmised, äriostud

FedEx CFO: MD-11 Grounding Led to $120M Headwind to Adjusted Operating Income in 3Q

19. märts 2026, 22:03 UTC

Market Talk

Uudisväärsed sündmused

Global Energy Roundup: Market Talk

19. märts 2026, 22:03 UTC

Market Talk

Uudisväärsed sündmused

Fuel Prices, Scarcity Could Leave Mark on Australia's Gold Miners -- Market Talk

19. märts 2026, 21:51 UTC

Tulu

Omandamised, ülevõtmised, äriostud

FedEx CEO: InPost Deal Expected to Be Accretive to Earnings in Year One After Close

19. märts 2026, 20:57 UTC

Uudisväärsed sündmused

Middle East Attacks, Inflation Fears Weigh on Stocks -- WSJ

19. märts 2026, 20:50 UTC

Market Talk

Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

19. märts 2026, 20:19 UTC

Uudisväärsed sündmused

Brent Crude Retreats After Touching $119 -- WSJ

19. märts 2026, 19:49 UTC

Market Talk

Brent Crude Seen Potentially Rising to Top Its 2008 High -- Market Talk

19. märts 2026, 19:26 UTC

Uudisväärsed sündmused

U.S. Consumers Face 'Global Oil Shock.' The Iran War Is Retail's Latest Challenge. -- Barrons.com

19. märts 2026, 19:10 UTC

Market Talk

Uudisväärsed sündmused

Natural Gas Rises in Volatile Trading -- Market Talk

19. märts 2026, 19:06 UTC

Uudisväärsed sündmused

Brent Crude Prices Are Surging. Why Europe Is Facing an Energy Shock and the U.S. Isn't. -- Barrons.com

19. märts 2026, 18:08 UTC

Market Talk

Uudisväärsed sündmused

Silver Extends Slide to Seven Straight Sessions -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Mirati Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

-0.05% langus

12 kuu keskmine prognoos

Keskmine 58.67 USD -0.05%

Kõrge 59 USD

Madal 58 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Mirati Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Mirati Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

155 / 350 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

Ettevõttest Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.